translational science

AcuraStem is a patient-based biotechnology company pioneering treatments for neurodegenerative diseases including sporadic ALS and FTD. It uses its proprietary disease-modeling platform iNeuroRx® to generate individual patient models that recapitulate neurodegenerative disease processes, aiming to discover novel, effective and broadly-acting treatments. The company has a growing pipeline of antisense oligonucleotide (ASO) treatments, including lead clinical candidate AS-241.

AIantisense oligonucleotide (ASO) therapeuticsBioinformaticsbiomarker developmentdisease modelingdrug discovery

Allterum Therapeutics is an early-stage biotechnology company developing precision oncology and inflammation therapeutics. Its lead program, 4A10, is an anti-CD127 monoclonal antibody targeting the CD127 pathway (IL-7 receptor complex) for relapsed leukemia, acute lymphoblastic leukemia, B-cell malignancies, lymphomas, and CD127-expressing solid tumors. The 4A10 antibody was developed at the National Cancer Institute and licensed exclusively to Fannin; Allterum is a Fannin portfolio company.

clinical developmentdrug developmentmonoclonal antibody developmentpreclinical studies

EicOsis Human Health is a clinical-stage pharmaceutical company developing oral medicines targeting soluble epoxide hydrolase (sEH) to treat pain, inflammation, and neuroinflammatory and neurological disorders. Its lead drug candidate, EC5026, is a first-in-class oral sEH inhibitor being studied as a non-opioid treatment for neuropathic pain, Parkinson's disease, Alzheimer's disease, and other conditions.

clinical trialsdrug discoverysEH inhibition